Clinical Trial Update: Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting results from Phase 2/3 studies of nalbuphine HCl extended-release tablets for uremic pruritus in hemodialysis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus
• Uremic Pruritus

Drugs mentioned

• Nalbuphine HCl ER Tablets (nalbuphine hydrochloride extended-release)

Snippet

Sponsor: Trevi Therapeutics | Conditions: Uremic Pruritus, Pruritus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-09-07